By Fineline Cube 
China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc. to develop novel in vivo chimeric antigen receptor (CAR)-T cell therapies targeting multiple indications.
Partnership Highlights
Umoja Biopharma brings to the collaboration its globally innovative VivoVec platform and GMP-compliant manufacturing processes. These technologies enable the in vivo generation of CAR-T cells directly within patients, offering more convenient and efficient treatment options. Oricell Therapeutics will contribute its core technologies in antibody discovery and CAR structure design, which have demonstrated best-in-class efficacy and safety profiles in clinical data from its tumor immunotherapy products, Ori-C101 and OriCAR-017.-Fineline Info & Tech